23 Feb VERIGRAFT
Petter Bjorquist, Ph.D., CEO
April 16 | 3:00pm | Salone dei Cavalieri, Section 2
Gothenburg, Sweden
(Private)
VERIGRAFT AB is a Swedish biotech company revolutionizing regenerative medicine with its cutting-edge tissue therapy solutions. At the core of its innovation is a proprietary technology that transforms donor tissues into personalized grafts, ensuring compatibility with the recipient’s immune system. This breakthrough 100% biocompatibility and eliminates the risk of rejection, setting a new standard for safety and efficacy in tissue transplants. VERIGRAFT’s current focus is on its flagship product, the Personalized Tissue Engineered Vein (P-TEV), designed to treat chronic venous insufficiency – a debilitating condition affecting millions worldwide. Backed by strong scientific expertise and ongoing clinical studies, VERIGRAFT is positioned to address unmet medical needs and deliver transformative therapies. With its commitment to advancing the future of regenerative medicine, VERIGRAFT aims to redefine patient care and improve outcomes for individuals who previously had limited or no treatment options.
